AstraZeneca Drops 5% on Bristol-Myers Deal Talks; Analysts Call It 'Odd'
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- AstraZeneca shares fell almost 5% while Bristol-Myers Squibb jumped 6% on Monday after the Financial Times and Bloomberg reported early-stage deal talks, which would rank among the biggest pharma mergers ever.
- Bank of America analysts led by Sachin Jain called the combination 'odd' for both companies, warning that for AstraZeneca it could signal a lack of confidence in its own pipeline.
- Jefferies analysts led by Michael Lechten said they were 'perplexed,' arguing that AstraZeneca is one company that 'doesn't need financial engineering' and could use any extra cash for R&D instead.
- Bank of America flagged that Bristol-Myers has a heavy slate of market-moving catalysts ahead, including studies on fibrosis drug admilparant, blood-clot drug Milvexian, and Cobenfy in Alzheimer's psychosis.
- Bristol-Myers Squibb trades at a 2027 earnings multiple of 10 versus 14 for AstraZeneca, per FactSet — but the gap reflects upcoming patent expirations on BMY drugs.
- Jefferies warned any deal would face tough regulatory hurdles, noting both companies already operate large oncology businesses that antitrust reviewers would scrutinize.
Why it matters: AstraZeneca's 5% slide versus Bristol-Myers' 6% gain reveals investors see BMY as the desperate party here — AZN trades at a premium multiple (14x vs 10x 2027 earnings) precisely because its pipeline doesn't need rescuing. The 'odd' verdict from both BofA and Jefferies suggests the deal, if it moves forward, will be judged on whether BMY's looming patent cliff can be offset by AstraZeneca's oncology strength — a thesis antitrust regulators may reject before shareholders ever vote.
